Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16417964 | 0.86 | HTT (0.49) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL18542867 | 0.85 | HTT (0.51) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL976356 | 0.85 | HTT (0.46) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL975464 | 0.80 | HTT (0.46) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL15744215 | 0.79 | HTT (0.43) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL890555 | 0.74 | HTT (0.49) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL18542826 | 0.74 | HTT (0.51) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL12196959 | 0.72 | HTT (0.41) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL975136 | 0.71 | GRIN1 (0.45) | HTTKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL890479 | 0.69 | HTT (0.43) | HTTKDM4EALDH1A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2018-12-20 | — | — | US | disclosed |
| US-9975907-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2448938-A1 | PYRIMIDINONES AS PI3K INHIBITORS | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2011008487-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008487-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | HTT 3196/4885KDM4E 1496/4885ALDH1A1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.